儿童系统性红斑狼疮的诊断与治疗
Diagnosis and treatment strategy of childhood-onset systemic lupus erythematosus
Received date: 2022-06-15
Online published: 2022-10-12
周纬 . 儿童系统性红斑狼疮的诊断与治疗[J]. 临床儿科杂志, 2022 , 40(10) : 721 -725 . DOI: 10.12372/jcp.2022.22e0849
Childhood-onset systemic lupus erythematosus (cSLE) is an autoimmune disease characterized by multiple organ involvement, a large number of autoantibodies and low complement. The affected organs are prone to irreversible damage, which threatens the lives of children. This article introduces the clinical characteristics of cSLE, severe lupus and monogenic lupus, and summarizes the diagnosis methods, disease activity assessment, treat-to-target, treatment principles and treatment schemes for different organ involvement of cSLE, and puts forward the treatment strategy of combination of traditional treatment and biological drugs, so as to better target the pathogenesis of cSLE, fully treat and control disease activity as soon as possible, reduce disease recurrence and side effects of traditional drugs, and provide reference for the continuous improvement of diagnosis and treatment of cSLE.
Key words： systemic lupus erythematosus; monogenic; biological drug; treat-to-target; child
| [1] | Tsokos GC. Systemic lupus erythematosus[J]. N Engl J Med, 2011, 365: 2110-2121. |
| [2] | 周纬, 殷蕾, 金燕樑. 儿童系统性红斑狼疮临床特征(附47例报告)[J]. 上海医学, 2008, 31(12): 843-845. |
| [3] | Kamphuis S, Silverman ED. Prevalence and burden of pediatric onset systemic lupus erythematosus[J]. Nat Rev Rheumatol, 2010, 6: 538-546. |
| [4] | 殷蕾, 周纬. 系统性红斑狼疮危象[J]. 中国小儿急救医学, 2020, 27(5): 324-329. |
| [5] | Kazzaz NM, Coit P, Lewis EE, et al. Systemic lupus erythematosus complicated by diffuse alveolar haemorrhage: risk factors, therapy and survival[J]. Lupus Sci Med, 2015, 2(1): e000117. |
| [6] | Ju JH, Min JK, Jung CK, et al. Lupus mesenteric vasculitis can cause acute abdominal pain in patients with SLE[J]. Nat Rev Rheumatol, 2009, 5(5): 273-281. |
| [7] | Alperin JM, Ortiz-Fernández L, Sawalha AH. Monogenic lupus: a developing paradigm of disease[J]. Front Immunol, 2018, 9: 2496. |
| [8] | Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus[J]. Ann Rheum Dis, 2019, 78: 1151-1159. |
| [9] | Al-Mayouf SM, Akbar L, Abdwani R, et al. Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematous in monogenic lupus[J]. Clin Rheumatol, 2022, doi: 10.1007/s10067-022-06209-9. |
| [10] | 中华医学会儿科学分会免疫学组中华儿科杂志编辑委员会. 中国儿童系统性红斑狼疮诊断与治疗指南[J]. 中华儿科杂志, 2021, 59(12) : 1009-1024. |
| [11] | Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus[J]. Arthritis Rheum, 1996, 39: 363-369. |
| [12] | Petri M, Magder LS. Comparison of remission and lupus low disease activity state in damage prevention in a United States systemic lupus erythematosus cohort[J]. Arthritis Rheumatol, 2018, 70: 1790-1795. |
| [13] | Wahadat MJ, van den Berg L, Timmermans D, et al. LLDAS is an attainable treat-to-target goal in childhood-onset SLE[J]. Lupus Sci Med, 2021, 8(1): e000571. |
| [14] | FranklynK, LauCS, NavarraSV, et al. Definition and initial validation of a lupus low disease activity state (LLDAS)[J]. Anna Rheuma Dis, 2015, 75 (9): 1615. |
| [15] | van Vollenhoven R, Voskuyl A, Bertsias G, et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)[J]. Ann Rheum Dis, 2017, 76: 554-561. |
| [16] | Atar D, Birkeland KI, Uhlig T. 'Treat to target': moving targets from hypertension, hyperlipidaemia and diabetes to heumatoid arthritis[J]. Ann Rheum Dis, 2010, 69: 629-630. |
| [17] | Kumar K, Gordon C, Toescu V, et al. Beliefs about medicines in patients with rheumatoid arthritis and systemic lupus erythematosus: a comparison between patients of south Asian and White British origin[J]. Rheumatology (Oxford), 2008, 47: 690-697. |
| [18] | Mok CC, Hamijoyo L, Kasitanon N, et al. The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus[J]. Lancet Rheumatol, 2021, 3: e517-e531. |
| [19] | Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review[J]. Ann Rheum Dis, 2010, 69: 20-28. |
| [20] | Mok CC, Yap DY, Navarra SV, et al. Overview of lupus nephritis management guidelines and perspective from Asia[J]. Int J Rheum Dis, 2013, 16(6): 625-636. |
| [21] | Buttgereit F, Straub RH, Wehling M, et al. Glucocorticoids in the treatment of rheumatic diseases:an update on the mechanisms of action[J]. Arthritis Rheum, 2004, 50: 3408-3417. |
| [22] | Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus[J]. Ann Rheum Dis, 2019, 78: 736-745. |
| [23] | KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases[J]. Kidney Int, 2021, 100(4S): S1-S276. |
| [24] | Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis[J]. N Engl J Med, 2005, 353: 2219-2228. |
| [25] | Isenberg D, Appel GB, Contreras G, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study[J]. Rheumatology (Oxford), 2010, 49: 128-140. |
| [26] | 王笑秋, 殷蕾, 茅幼英, 等. 多靶点治疗儿童狼疮肾炎的疗效观察[J]. 中华风湿病学杂志, 2014, 18(9): 47-51. |
| [27] | Weidenbusch M, Römmele C, Schröttle A, Anders HJ. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis[J]. Nephrol Dial Transplant, 2013, 28: 106-111. |
| [28] | Lorenz G, Schul L, Schraml F, et al. Adult macro-phage activation syndrome-haemophagocytic lymphohistiocytosis: ‘of plasma exchange and immunosuppressive escalation strategies’ - a single centre reflection[J]. Lupus, 2020, 29: 324-333. |
/
| 〈 |
|
〉 |
沪公网安备 31011002000392号
